OxFORD Asset Management LLP Acquires Shares of 20,365 AtriCure Inc. (ATRC)

OxFORD Asset Management LLP acquired a new position in AtriCure Inc. (NASDAQ:ATRC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,365 shares of the medical device company’s stock, valued at approximately $457,000. OxFORD Asset Management LLP owned about 0.06% of AtriCure at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the company. FMR LLC raised its position in AtriCure by 2.4% during the 2nd quarter. FMR LLC now owns 5,068,247 shares of the medical device company’s stock valued at $122,905,000 after purchasing an additional 118,247 shares in the last quarter. Vanguard Group Inc. raised its position in AtriCure by 3.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,446,732 shares of the medical device company’s stock valued at $35,083,000 after purchasing an additional 52,761 shares in the last quarter. Victory Capital Management Inc. raised its position in AtriCure by 1.4% during the 2nd quarter. Victory Capital Management Inc. now owns 1,319,475 shares of the medical device company’s stock valued at $31,998,000 after purchasing an additional 18,536 shares in the last quarter. First Light Asset Management LLC raised its position in AtriCure by 0.3% during the 2nd quarter. First Light Asset Management LLC now owns 958,858 shares of the medical device company’s stock valued at $23,252,000 after purchasing an additional 2,400 shares in the last quarter. Finally, Peregrine Capital Management LLC raised its position in AtriCure by 3.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 924,740 shares of the medical device company’s stock valued at $20,686,000 after purchasing an additional 31,526 shares in the last quarter. Hedge funds and other institutional investors own 86.17% of the company’s stock.

In other AtriCure news, CFO M. Andrew Wade sold 2,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total transaction of $36,820.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director B Kristine Johnson purchased 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was bought at an average cost of $18.36 per share, with a total value of $27,540.00. Following the acquisition, the director now owns 10,969 shares of the company’s stock, valued at approximately $201,390.84. The disclosure for this purchase can be found here. Corporate insiders own 11.90% of the company’s stock.

Shares of AtriCure Inc. (NASDAQ:ATRC) opened at $17.69 on Friday. AtriCure Inc. has a one year low of $14.78 and a one year high of $25.18. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $609.85, a PE ratio of -17.34 and a beta of 0.66.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The firm had revenue of $42.20 million for the quarter, compared to the consensus estimate of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) earnings per share. research analysts expect that AtriCure Inc. will post -0.96 EPS for the current fiscal year.

ATRC has been the subject of several recent research reports. Piper Jaffray Companies reissued a “buy” rating and issued a $24.00 price target on shares of AtriCure in a research report on Sunday, December 10th. ValuEngine lowered AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. TheStreet lowered AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Zacks Investment Research raised AtriCure from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 target price on shares of AtriCure in a research report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $24.67.

TRADEMARK VIOLATION WARNING: “OxFORD Asset Management LLP Acquires Shares of 20,365 AtriCure Inc. (ATRC)” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://stocknewstimes.com/2018/01/12/20365-shares-in-atricure-inc-atrc-acquired-by-oxford-asset-management-llp-5.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply